- Home
- HCWB vs SILO Comparison
HCWB vs SILO Comparison
Compare HCWB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- SILO
- Stock Information
- Founded
- HCWB 2018
- SILO 2010
- Country
- HCWB United States
- SILO United States
- Employees
- HCWB N/A
- SILO N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- HCWB Health Care
- SILO Consumer Discretionary
- Exchange
- HCWB Nasdaq
- SILO Nasdaq
- Market Cap
- HCWB 8.4M
- SILO 8.0M
- IPO Year
- HCWB 2021
- SILO N/A
- Fundamental
- Price
- HCWB $3.89
- SILO $0.55
- Analyst Decision
- HCWB Strong Buy
- SILO
- Analyst Count
- HCWB 1
- SILO 0
- Target Price
- HCWB $35.00
- SILO N/A
- AVG Volume (30 Days)
- HCWB 94.5K
- SILO 813.6K
- Earning Date
- HCWB 11-13-2025
- SILO 11-12-2025
- Dividend Yield
- HCWB N/A
- SILO N/A
- EPS Growth
- HCWB N/A
- SILO N/A
- EPS
- HCWB N/A
- SILO N/A
- Revenue
- HCWB $832,841.00
- SILO $72,102.00
- Revenue This Year
- HCWB $178.64
- SILO $1.86
- Revenue Next Year
- HCWB N/A
- SILO N/A
- P/E Ratio
- HCWB N/A
- SILO N/A
- Revenue Growth
- HCWB N/A
- SILO N/A
- 52 Week Low
- HCWB $2.77
- SILO $0.40
- 52 Week High
- HCWB $100.80
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- HCWB 45.35
- SILO 40.03
- Support Level
- HCWB $4.00
- SILO $0.53
- Resistance Level
- HCWB $4.07
- SILO $0.62
- Average True Range (ATR)
- HCWB 0.22
- SILO 0.06
- MACD
- HCWB -0.02
- SILO -0.01
- Stochastic Oscillator
- HCWB 4.76
- SILO 50.83
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.